Jul 24, 2017 4:05 pm EDT CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Jul 17, 2017 7:30 am EDT CymaBay Announces Positive Interim Results from Its Ongoing Low-Dose Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis
Jun 26, 2017 8:00 am EDT CymaBay Announces the Appointment of Klara Dickinson as Senior Vice President, Regulatory Affairs and Quality Assurance and the Promotion of Daniel Menold to Vice President, Finance
May 11, 2017 4:01 pm EDT CymaBay Reports First Quarter 2017 Financial Results and Provides Corporate Update
Apr 13, 2017 8:00 am EDT CymaBay to Present Data from its Phase 2 Proof-of-Concept Study of Seladelpar in Patients With Primary Biliary Cholangitis at the EASL Liver Meeting 2017
Mar 29, 2017 8:00 am EDT CymaBay Announces the Retirement of President and Chief Executive Officer, Harold Van Wart, Ph.D.